表紙
市場調査レポート

C型肝炎治療薬:世界の産業・R&D・市場予測

Hepatitis C Therapies: World Industry, R&D and Market Forecasts 2015-2025

発行 Visiongain Ltd 商品コード 320321
出版日 ページ情報 英文 196 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=142.08円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
C型肝炎治療薬:世界の産業・R&D・市場予測 Hepatitis C Therapies: World Industry, R&D and Market Forecasts 2015-2025
出版日: 2014年12月02日 ページ情報: 英文 196 Pages
概要

2015年以降のC型肝炎治療薬の市場は、投資、技術、医学的進歩、売上の面で大きく飛躍する可能性を秘めており、世界のC型肝炎治療薬の市場は2018年には320億ドルの規模に達し、2014年から2025年にかけて高い収益性を維持すると予測されています。

当レポートでは、C型肝炎治療薬の市場について調査し、C型肝炎および治療薬の概要、収益規模の推移と予測、薬剤区分および主要国別の内訳、主要ブランドの収益予測および市場シェア、パイプラインと候補化合物の動向、主要企業のプロファイル、市場動向の分析、専門家へのインタビューなどをまとめています。

第1章 レポート概要

第2章 イントロダクション:C型肝炎治療薬

  • C型肝炎および治療薬の概要
  • 発症と罹患のパターン
  • C型肝炎:治療薬と予防
    • 抗ウイルス薬:ウイルスの複製の阻害
    • インターフェロン:2つの作用機序
    • C型肝炎とワクチンのニーズ

第3章 世界のC型肝炎治療薬市場の予測

  • C型肝炎治療薬市場:2013年・2014年
  • C型肝炎治療薬市場:収益予測
    • 意識の向上とスクリーニング:治療人口の増加
    • C型肝炎治療薬市場におけるジェネリックの競争
    • バイオシミラーインターフェロン
    • 直接作用型抗ウイルス薬 (DAA):治療環境の変化
  • 経口抗ウイルス薬市場
    • 経口抗ウイルス薬市場:収益予測、など
  • インターフェロン市場
    • インターフェロン市場:収益予測、など
  • C型肝炎ワクチン市場
  • C型肝炎治療薬:下位市場の市場シェア実績・予測

第4章 主要国のC型肝炎市場の予測

  • 世界のC型肝炎発症数
  • C型肝炎治療薬市場:地域の内訳
  • C型肝炎治療薬市場:地域の内訳の予測
  • 米国
  • 主なEU市場
    • 地域の発症数
    • EU5市場の実績
    • EU5
    • イタリア
    • スペイン
    • ドイツ
    • 英国
    • フランス
  • アジアのC型肝炎
  • 中国
  • 日本
  • インド
  • ロシア
  • ブラジル
    • 収益予測、など

第5章 主なC型肝炎治療薬市場の展望

  • 主なC型肝炎治療薬の予測
  • Sovaldi (Gilead Sciences)
  • Olysio (Janssen/Medivir)
  • Pegasys (Roche)
  • Incivek (Vertex/Janssen (J&J)/田辺三菱製薬)
  • PegIntron (Merck & Co.)
  • Victrelis (Merck & Co.)
  • Harvoni (Gilead Sciences)
  • Daklinza (Bristol-Myers Squibb)
  • Sunvepra (Bristol-Myers Squibb)

第6章 C型肝炎治療薬市場:主なR&Dパイプライン候補化合物

  • イントロダクション:C型肝炎治療の候補化合物
  • プロテアーゼ阻害剤のパイプライン
    • Vaniprevir (Merck & Co.)
    • MK-5172 and MK-8742 (Merck & Co.)
    • Paritaprevir (formerly ABT-450) (AbbVie)
    • Sovaprevir (Achillion Pharmaceuticals)
    • ACH-2684 (Achillion Pharmaceuticals)
    • Danoprevir (Roche)
    • Lomibuvir (Vertex Pharmaceuticals)
    • ABT-493 (AbbVie)
    • Vedroprevir (Gilead Sciences)
    • GS-9857 (Gilead Sciences)
  • Pポリメラーゼ阻害剤 のパイプライン
    • ACH-2928 (Achillion Pharmaceuticals)
    • BMS-791325 (Bristol-Myers Squibb)
    • TMC-647055 (Janssen)
    • Mercitabine (Roche/Pharmasset)
    • Setrobuvir (Roche)
    • VX-135 (Vertex Pharmaceuticals)
    • GS-9669 (Gilead Sciences)
    • PPI-383 (Presidio Pharmaceuticals)
  • NS5A阻害剤のパイプライン
    • ABT-530 (AbbVie)
    • Samatisvir (Merck & Co.)
    • GS-5816 (Gilead Sciences)
    • PPI-668 (Presidio Pharmaceuticals)
  • インターフェロンのパイプライン
    • Locteron (Biolex)
    • Peginterferon Lambda-1a (Bristol-Myers Squibb)
  • 新しい阻害剤
    • SCY-635 (SCYNEXIS)
    • Miraversen (Santaris)
    • GS-9620 (Gilead Sciences)
    • RG-101 (Regulus Therapeutics)
  • 保留中・中止のC型肝炎パイプライン候補化合物
    • Alisporivir (Novartis/Debiopharm)
    • INX-189 (Bristol-Myers Squibb)
    • Idenix Developments Terminated
    • Deleobuvir (Boehringer Ingelheim)
    • Faldaprevir (Boehringer Ingelheim)
  • 主なC型肝炎ワクチンのパイプライン候補
    • ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals)
    • GI-5005 (GlobeImmune)
    • INO-8000 HCV (Inovio Pharmaceuticals)
    • Okairos Inc.

第7章 主要企業

  • 主要企業
  • Gilead Sciences
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Roche
  • Bristol-Myers Squibb
  • Merck & Co.

第8章 C型肝炎治療薬市場:産業動向の予測

  • C型肝炎治療薬市場の強み・弱み
  • C型肝炎治療薬市場の市場機会・脅威
  • STEP分析
  • C型肝炎ワクチン
  • 経口直接作用型抗ウイルス薬
  • C型肝炎への投資

第9章 リサーチインタビュー

第10章 総論

  • 肝炎治療薬市場の動向
  • 肝炎治療薬市場の成長
  • まとめ

図表

目次
Product Code: PHA0016

Hepatitis C treatments - your guide to medical needs, R&D trends and future drug revenues

Discover the future of treating hepatitis C virus (HCV). Now you can get sales forecasts and explore that industry's research and development. See where the money lies from 2014. And find where that technology heads.

Visiongain's new guide predicts those revenues to 2025 at overall world, submarket, product and national level. Its purpose is to help you stay ahead in data, news and analysis on those therapies. It examines medical, technological and commercial potentials and opportunities.

Can that that large, profitable market sustain revenue growth? Please read on to explore HCV medicines and their producers, seeing how high that industry's sales can go.

Forecasts and other analyses to help your research, knowledge and influence

Avoid struggles to find business information on that viral infection. Instead discover what's happening in technology and demand for therapy. With our investigation you can make your research, appraisals and commercial decisions on hepatitis C treatments quicker and easier.

  • Who is the company with the highest expected revenue from 2015 to 2025?
  • What technologies give the most promising candidates for new drugs?
  • Where lie the best geographical opportunities for selling those antivirals?
  • Why will the HCV drug market expand, and what limits its sales growth?
  • When will that industry achieve fastest expansion and peak revenues?
  • How will companies overcome challenges in serving regulators, patients and payers?

Besides sales predictions to 2025, our study presents recent results, growth rates, market shares and discussions. You get 69 tables, 53 charts and two interviews with authorities.

Forecasting of the world HCV therapy market and its segments

Our report predicts overall world revenue to 2025 for those anti-infective drugs. There you also find individual revenue predictions to 2025 for two submarkets at world level:

  • Oral antiviral agents
  • Interferons for treating that disorder.

For treating that infectious disease, especially of the liver, discover how competition and technological advances shape the industry. So benefit your reputation for commercial knowledge. And find where the most money and best prospects for commercial growth exist.

Also assess leading pharmaceutical brands for tackling those chronic infections.

Forecasts for HCV medicines - see potentials for top brands

How will six leading and three emerging drugs perform to 2025 at world level? Our study forecasts individual revenues of nine agents:

  • Sovaldi (sofosbuvir)
  • Olysio (simeprevir)
  • Pegasys (peginterferon alfa-2a)
  • Incivek and related brands (telaprevir)
  • PegIntron (peginterferon alfa-2b)
  • Victrelis (boceprevir)
  • Harvoni (ledipasvir and sofosbuvir)
  • Daklinza (daclatasvir)
  • Sunvepra (asunaprevir).

Those analyses show you how high sales can go. There find products and years with highest predicted expansion and revenues. You hear what's happening. And you deepen your understanding of trends, competition, challenges and opportunities.

In that work you also find national revenue predictions.

Healthcare in regional markets - what outlooks for that business?

Our investigation also shows you individual revenue forecasts to 2025 for 11 countries:

  • United States (US)
  • Japan
  • Germany, France, UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC nations).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that industry and market?

Forces, events and issues - developments influencing those antiviral treatments

That new report explains policies, trends and R&D shaping the industry and market, including these influences:

  • Protease, polymerase and NS5A inhibitors, interferons, vaccines and other agents - explore drug development, viewing prospects for future therapies
  • Combination therapy - hepatitis C treatment via interferons and antivirals
  • Interferon-free regimens, prophylactic and personalised medicine tackling genotypes
  • Direct-acting antivirals (DAAs) - a change in therapeutic procedures
  • Generics and biosimilars - rising competition for original brands, including follow-on biological drugs
  • Licensing, partnering and acquisition deals - collaborations among developers, manufacturers and marketers.

There you assess that industry's strengths, weaknesses, opportunities and threats. Also explore social, technological, economic and political questions. Those analyses give you feel for that market - its progress, potential and opportunities, reducing your risk of falling behind.

Developers, manufacturers, sellers and 2018 market value - what happens next?

From 2015 HCV treatments hold great potential for investments, technologies, medical advances and sales. Our analyses predict the overall world market for those products will reach $32bn in 2018, with high revenues from 2014 to 2025.

That work also explores activities and potentials of these companies in particular:

  • Gilead Sciences
  • Janssen Pharmaceutica
  • Roche
  • Bristol-Myers Squibb
  • Merck & Co.
  • AbbVie
  • Achillion Pharmaceuticals.

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

Ways Hepatitis C Therapies: World Industry, R&D and Market Forecasts 2015-2025 helps

That new market assessment benefits research, analysis and planning in eight main ways:

  • World HCV market revenue to 2025 - discover that industry's overall sales potential
  • Two product classes' revenues to 2025 - investigate categories at world level, finding the most lucrative and promising therapy classes
  • Nine leading drugs' revenues to 2025 - find sales predictions for top and emerging products, seeing how agents compete and succeed
  • 11 national markets in the Americas, Europe and Asia covered, with forecasts to 2025 - discover the best countries for trade expansion
  • Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances, collaborations and outlooks
  • R&D for those antiviral medicines - investigate progress in that industry, exploring technological, clinical and commercial opportunities
  • Interviews with two organisations - discover other experts' views, gaining insight to benefit your work
  • Analysis of what stimulates and restrains that industry and market - assess challenges, strengths, competition and opportunities, helping you succeed.

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects

For treating hepatitis C virus, our report shows you data, trends, opportunities and multilevel sales forecasts. So avoid missing out. Instead please get that new analysis here now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Hepatitis C Therapies
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by this Analysis
  • 1.5 Who is this Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Hepatitis C Therapies

  • 2.1 A Brief History of Hepatitis C and Treatments
    • 2.1.1 Genotypes
    • 2.1.2 Symptoms: Acute and Chronic Hepatitis C
    • 2.1.3 Diagnosing Hepatitis C: The Asymptomatic Nature
    • 2.1.4 Risk Factors for Hepatitis C
  • 2.2 Incidence and Prevalence Patterns
  • 2.3 Hepatitis C: Treatment and Prevention
    • 2.3.1 Antivirals: Inhibiting Virus Replication
      • 2.3.1.1 Protease Inhibitors
      • 2.3.1.2 Polymerase Inhibitors
      • 2.3.1.3 NS5A Replication Complex Inhibitors
    • 2.3.2 Interferons: Dual Mode of Action
      • 2.3.2.1 Combination Therapy: Treatment with Interferons and Antivirals
      • 2.3.2.2 Interferon-Free Regimens
    • 2.3.3 Hepatitis C and the Need for a Vaccine

3. The World Hepatitis C Therapies Market, 2015-2025

  • 3.1 Hepatitis C Therapies Market, 2013 and 2014
  • 3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2014-2025
    • 3.2.1 Rising Awareness and Screening: Expanding Treatment Population
    • 3.2.2 Generic Competition in the Hepatitis C Therapies Market
    • 3.2.3 Biosimilar Interferons
    • 3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
  • 3.3 Oral Antivirals Submarket
    • 3.3.1 Oral Antivirals Submarket: Revenue Forecast, 2014-2025
    • 3.3.2 A Strong Developmental Pipeline to Drive Market Growth
    • 3.3.3 All-Oral Treatments for Hepatitis C: Improving Tolerability
  • 3.4 Interferons Submarket
    • 3.4.1 Standard of Care for Hepatitis C
    • 3.4.2 Drawbacks to Interferon Therapy
    • 3.4.3 Declining Revenues 2008-2013
    • 3.4.4 Interferons Submarket: Revenue Forecast, 2014-2025
    • 3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
  • 3.5 Hepatitis C Vaccines Submarket
  • 3.6 Hepatitis C Therapies: Submarket Shares 2013, 2019 and 2025

4. Leading National Hepatitis C Markets, 2015-2025

  • 4.1 Global Prevalence of Hepatitis C, 2013
    • 4.1.1 The Importance of Asia
  • 4.2 Hepatitis C Therapies Market: Regional Breakdown, 2013
  • 4.3 Hepatitis C Therapies Market: Regional Forecast, 2014-2025
  • 4.4 The US
    • 4.4.1 Population Movement and Hepatitis C
    • 4.4.2 The Affordable Care Act and Hepatitis C
    • 4.4.3 Increased Screening towards Target Population
    • 4.4.4 The US Revenue Forecast, 2014-2025
  • 4.5 Leading EU Markets for Hepatitis C Therapies
    • 4.5.1 Regional Prevalence
    • 4.5.2 EU5 Market, 2013
    • 4.5.3 EU5: Revenue Forecasts, 2014-2025
    • 4.5.4 Italy: Revenue Forecast, 2014-2025
    • 4.5.5 Spain: Revenue Forecast, 2014-2025
    • 4.5.6 Germany: Revenue Forecast, 2014-2025
    • 4.5.7 UK: Revenue Forecast, 2014-2025
    • 4.5.8 France: Revenue Forecast, 2014-2025
  • 4.6 Hepatitis C in Asia
  • 4.7 China
    • 4.7.1 Decline in Incidence of Hepatitis C
    • 4.7.2 Rising Middle Class
    • 4.7.3 Hepatitis C Outbreaks
    • 4.7.4 Domestic Drug and Vaccine Development
    • 4.7.5 China: Revenue Forecast, 2014-2025
  • 4.8 Japan
    • 4.8.1 Hepatitis C in Japan
    • 4.8.2 Japan: Revenue Forecast, 2014-2025
  • 4.9 India
    • 4.9.1 Low Awareness Rates
    • 4.9.2 India: Revenue Forecast, 2014-2025
  • 4.10 Russia
    • 4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
    • 4.10.2 Adverse Impact of Western Sanctions on Russian Pharma Market
    • 4.10.3 Russia: Revenue Forecast, 2014-2025
  • 4.11 Brazil
    • 4.11.1Current Disease Prevalence
    • 4.11.2 Brazil: Revenue Forecast, 2014-2025

5. Leading Hepatitis C Therapies, Market Prospects to 2025

  • 5.1 Leading Hepatitis C Therapies, 2014-2025
  • 5.2 Sovaldi (Gilead Sciences)
    • 5.2.1 Recent Revenue Analysis
    • 5.2.2 Gilead Licenses Generic Substitute for Sovaldi for Developing Countries
    • 5.2.3 Sovaldi Revenue Forecast, 2014-2025
  • 5.3 Olysio (Janssen/Medivir)
    • 5.3.1 Recent Revenue Analysis
    • 5.3.2 Combination Regimen of Sovaldi and Olysio
    • 5.3.3 Olysio Revenue Forecast, 2014-2025
  • 5.4 Pegasys (Roche)
    • 5.4.1 Recent Revenue Analysis
    • 5.4.2 Label Expansions and Lifecycle Management Strategies
    • 5.4.3 Pegasys Revenue Forecast, 2014-2025
  • 5.5 Incivek (Vertex/Janssen (J&J)/Mitsubishi Tanabe)
    • 5.5.1 Recent Revenue Analysis
    • 5.5.2 Targeting HCV/HIV Co-Infected Patients
    • 5.5.3 Pipeline Competition May Affect Revenues
    • 5.5.4 Incivek Revenue Forecast, 2014-2025
  • 5.6 PegIntron (Merck & Co.)
    • 5.6.1 Recent Revenue Analysis
    • 5.6.2 Competition from Interferon Biosimilars
    • 5.6.3 Enhancing Drug Life Cycle
    • 5.6.4 PegIntron Revenue Forecast, 2014-2025
  • 5.7 Victrelis (Merck & Co.)
    • 5.7.1 Recent Revenue Analysis
    • 5.7.2 Roche Collaboration
    • 5.7.3 Product Differentiation
    • 5.7.4 Victrelis Revenue Forecast, 2014-2025
  • 5.8 Harvoni (Gilead Sciences)
    • 5.8.1 Gilead-AbbVie Dispute over Ledipasvir/Sofosbuvir Patents
    • 5.8.2Harvoni Revenue Forecast, 2014-2025
  • 5.9 Daklinza (Bristol-Myers Squibb)
    • 5.9.1 Daklinza Revenue Forecast, 2014-2025
  • 5.10 Sunvepra (Bristol-Myers Squibb)
    • 5.10.1 Sunvepra: Synergistic Effect with Daklinza
    • 5.10.2 Sunvepra Revenue Forecast, 2014-2025

6. Hepatitis C Therapies Market: Leading R&D Pipeline Candidates, 2014

  • 6.1 Introduction to Hepatitis C Therapy Candidates
  • 6.2 Protease Inhibitors Pipeline
    • 6.2.1 Vaniprevir (Merck & Co.): Patent Security through 2027
    • 6.2.2 MK-5172 and MK-8742 (Merck & Co.): Phase III
    • 6.2.3 Paritaprevir (formerly ABT-450) (AbbVie): Fast-Tracked into Phase III
    • 6.2.4 Sovaprevir (Achillion Pharmaceuticals): Playing Catch Up
    • 6.2.5 ACH-2684 (Achillion Pharmaceuticals)
    • 6.2.6 Danoprevir (Roche): Testing Out Combination Regimens
    • 6.2.7 Lomibuvir (Vertex Pharmaceuticals)
    • 6.2.8 ABT-493 (AbbVie)
    • 6.2.9 Vedroprevir (Gilead Sciences)
    • 6.2.10 GS-9857 (Gilead Sciences)
  • 6.3 Polymerase Inhibitors Pipeline
    • 6.3.1 ACH-2928 (Achillion Pharmaceuticals)
    • 6.3.2 BMS-791325 (Bristol-Myers Squibb): Phase II
    • 6.3.3 TMC-647055 (Janssen): Phase II
    • 6.3.4 Mercitabine (Roche/Pharmasset): Broad Spectrum Treatment
    • 6.3.5 Setrobuvir (Roche): Non-Nucleoside Inhibitor
    • 6.3.6 VX-135 (Vertex Pharmaceuticals): Interferon- and Ribavirin-Free Regimens
    • 6.3.7 GS-9669 (Gilead Sciences)
    • 6.3.8 PPI-383 (Presidio Pharmaceuticals)
  • 6.4 NS5A Inhibitors Pipeline
    • 6.4.1 ABT-530 (AbbVie)
    • 6.4.2 Samatisvir (Merck & Co.): Acquired from Idenix
    • 6.4.3 GS-5816 (Gilead Sciences)
    • 6.4.4 PPI-668 (Presidio Pharmaceuticals)
  • 6.5 Interferon Pipeline
    • 6.5.1 Locteron (Biolex): Controlled Release Formulation
    • 6.5.2 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effects Profile
  • 6.6 Novel Inhibitors
    • 6.6.1 SCY-635 (SCYNEXIS)
    • 6.6.2 Miraversen (Santaris)
    • 6.6.3 GS-9620 (Gilead Sciences)
    • 6.6.4 RG-101 (Regulus Therapeutics)
  • 6.7 Hepatitis C Pipeline Candidates on Hold or Discontinued, 2014
    • 6.7.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophin Inhibitor
    • 6.7.2 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
    • 6.7.3 Idenix Developments Terminated: IDX-189 and IDX-19368
    • 6.7.4 Deleobuvir (Boehringer Ingelheim): Development Discontinued
    • 6.7.5 Faldaprevir (Boehringer Ingelheim): Exiting the Hepatitis C Market
  • 6.8 Leading Hepatitis C Vaccine Pipeline Candidates, 2014
    • 6.8.1 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
    • 6.8.2 GI-5005 (GlobeImmune): Yeast-Based Hepatitis C Vaccine
    • 6.8.3 INO-8000 HCV (Inovio Pharmaceuticals): Therapeutic Vaccine in Phase I Trials
    • 6.8.4 Okairos Inc.: Prophylactic and Therapeutic Vaccine Candidates

7. Leading Companies in the Hepatitis C Therapies Market

  • 7.1 Leading Market Players, 2013 and 2014
  • 7.2 Gilead Sciences
    • 7.2.1 Product Overview and Performance. 2013 and 2014
    • 7.2.2 Recent Developments: Gilead Sciences Acquires Pharmasset
    • 7.2.3 Hepatitis Pipeline: Strong and Diverse
    • 7.2.4 Future Outlook: Strongest Pipeline than Any Other Company
  • 7.3 Johnson & Johnson (Janssen Pharmaceuticals)
    • 7.3.1 Product Overview and Performance, 2013 and 2014
    • 7.3.2 Recent Developments: Acquisition of Alios BioPharma
    • 7.3.3 Hepatitis Pipeline
    • 7.3.4 Future Outlook: Combination Regimens with Olysio
  • 7.4 Roche
    • 7.4.1 Product Overview and Performance. 2013 and 2014
    • 7.4.2 Recent Developments: Partnership with Anadys
    • 7.4.3 Hepatitis Pipeline
    • 7.4.4 Future Outlook: Slowing Demand May Affect Market Dominance
  • 7.5 Bristol-Myers Squibb
    • 7.5.1 Product Overview and Performance. 2013 and 2014
    • 7.5.2 Recent Developments: Strengthening Product Pipeline through Acquisitions
    • 7.5.2.1 Bristol-Myers Squibb Acquires Inhibitex
    • 7.5.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
    • 7.5.4 Future Outlook: Market Set For Intense Competition
  • 7.6 Merck & Co.
    • 7.6.1 Product Overview and Performance. 2013 and 2014
    • 7.6.2 Recent Developments: Merck & Co. Acquires Idenix
    • 7.6.3 Hepatitis Pipeline
    • 7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
  • 7.7 Leading Hepatitis C Pipeline Companies, 2014
    • 7.7.1 Gilead Sciences
    • 7.7.2 Merck & Co.
    • 7.7.3 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
    • 7.7.4 Achillion Pharmaceuticals: Next Target for Acquisition
    • 7.7.4.1 Achillion and Gilead

8. Hepatitis C Therapies Market: Industry Trends, 2015-2025

  • 8.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2014-2025
    • 8.1.1 Interferon Therapy Has Drawbacks
    • 8.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
  • 8.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2014-2025
    • 8.2.1 Hepatitis Screening and Diagnosis
    • 8.2.2 Raising Awareness and Overcoming Social Stigma
    • 8.2.3 Personalised Therapy
    • 8.2.4 HIV Co-Infection
    • 8.2.5 Asia
  • 8.3 STEP Analysis of The World Hepatitis C Therapies Market, 2014-2025
    • 8.3.1 Social Development
    • 8.3.1.1 Social Implications in China
    • 8.3.2 Technological Advances
    • 8.3.3 Economic Pressures
    • 8.3.4 Political Issues
  • 8.4 Hepatitis C Vaccines
  • 8.5 Oral Direct-Acting Antivirals
    • 8.5.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
    • 8.5.2 Combining Protease and Polymerase Inhibitors
    • 8.5.3 The Need for Ribavirin
    • 8.5.4 Twelve-Week Treatment Target
  • 8.6 Pharmaceutical Investment in Hepatitis C
    • 8.6.1 Licensing and Partnering Deals
    • 8.6.2 Acquisitions in Hepatitis C
    • 8.6.3 Other Companies of Note for Hepatitis Treatment Developments

9. Research Interviews

  • 9.1 Expert Interview 1: Authority from a Company in the Industry (Views Provided Anonymously)
    • 9.1.1 The Hepatitis C Therapies Market Landscape
    • 9.1.2 Interferon Therapies
    • 9.1.3 The Future Hepatitis C Therapies Market
  • 9.2 Interview with Susan Simon, President of the Hepatitis C Association
    • 9.2.1 Barriers to Treatment
    • 9.2.2 Changes to Treatment in the Past Decade and Coming Years
    • 9.2.3 Support and Awareness for Hepatitis C

10. Conclusions

  • 10.1 State of The Hepatitis Therapies Market, 2013 and 2014
  • 10.2 Growth in The Hepatitis Therapies Market, 2014-2025
    • 10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
    • 10.2.2 Asia as a Hepatitis C Therapies Market
  • 10.3 Concluding Remarks

List of Tables

  • Table 1.1 Submarket Forecasts of Hepatitis C Therapies, 2013-2019
  • Table 1.2 Submarket Forecasts of Hepatitis C Therapies, 2019-2025
  • Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD
  • Table 2.1 Global Pattern of Hepatitis C Genotypes and Subtypes, 2014
  • Table 2.2 Approved Antiviral Subtypes for Hepatitis C, 2014
  • Table 3.1 Hepatitis C Therapies Market ($bn and %) by Sector, 2013
  • Table 3.2 Hepatitis C Therapies Market ($bn and %) by Sector, 2014
  • Table 3.3 Hepatitis C Therapies Market: Overall Market Forecast of Currently Approved Drugs and Predicted Approvals ($bn), 2014-2025
  • Table 3.4 Hepatitis C Therapies Market: Revenue Forecasts by Segment ($bn), 2014-2025
  • Table 3.5 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging National Markets, 2013
  • Table 3.6 Leading Hepatitis C Antivirals: Revenue Shares by Drug ($bn and %), 2013
  • Table 3.7 Oral Antivirals Submarket: Revenue Forecast ($bn), 2014-2025
  • Table 3.8 Interferons Submarket: Revenue ($bn) and Market Share (%) by Drug, 2013
  • Table 3.9 Interferons Submarket: Revenue Forecast ($bn), 2014-2025
  • Table 3.10 Hepatitis C Submarket Shares (%), 2013, 2019 & 2025
  • Table 4.1 Global Prevalence of Chronic Hepatitis C, 2013
  • Table 4.2 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Region, 2013
  • Table 4.3 Hepatitis C Therapies: Overall Market and Revenue Forecasts ($bn) by Region, 2014-2025
  • Table 4.4 US Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.5 EU5 Hepatitis C Therapies: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2013
  • Table 4.6 EU5 Hepatitis C Therapies Market: Overall Revenue Forecast ($bn), 2014-2025
  • Table 4.7 Italian Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.8 Spanish Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.9 German Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.10 UK Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.11 French Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.12 Chinese Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.13 Japanese Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.14 Indian Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.15 Russian Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 4.16 Brazilian Hepatitis C Therapies: Forecast ($bn), 2014-2025
  • Table 5.1 Selected Leading Hepatitis C Therapies ($bn and %), 2013
  • Table 5.2 Sovaldi: Key Facts, 2014
  • Table 5.3 Sovaldi: Revenue ($bn) by Region, Q1-Q3, 2014
  • Table 5.4 Sovaldi: Revenue Forecast ($bn), 2014-2025
  • Table 5.5 Olysio: Key Facts, 2014
  • Table 5.6 Olysio: Revenue ($bn) by Region, Q1-Q3, 2014
  • Table 5.7 Olysio: Revenue Forecast ($bn), 2014-2025
  • Table 5.8 Pegasys: Key Facts, 2014
  • Table 5.9 Pegasys: Revenue Forecast ($bn), 2014-2025
  • Table 5.10 Incivek: Key Facts, 2014
  • Table 5.11 Incivek: Revenue ($bn) and Market Share (%) by Region, 2013
  • Table 5.12 Incivek: Revenue Forecast ($bn), 2014-2025
  • Table 5.13 PegIntron: Key Facts, 2014
  • Table 5.14 PegIntron: Revenue Forecast ($bn), 2014-2025
  • Table 5.15 Victrelis: Key Facts, 2014
  • Table 5.16 Victrelis: Revenue Forecast ($bn), 2014-2025
  • Table 5.17 Harvoni: Key Facts, 2014
  • Table 5.18 Harvoni: Revenue Forecast ($bn), 2014-2025
  • Table 5.19 Daklinza: Key Facts, 2014
  • Table 5.20 Daklinza: Revenue Forecast ($bn), 2014-2025
  • Table 5.21 Sunvepra: Key Facts, 2014
  • Table 5.22 Sunvepra: Revenue Forecast ($bn), 2014-2025
  • Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2014
  • Table 7.1 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Company, 2013
  • Table 7.2 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Company, 2014
  • Table 7.3 Gilead Sciences: Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013
  • Table 7.4 Gilead Sciences: Hepatitis C Pipeline, 2014
  • Table 7.5 Roche: Hepatitis C Pipeline, 2014
  • Table 7.6 Pegasys: Revenue ($bn) and Market Share (%), 2013, 2019 & 2025
  • Table 7.7 Bristol-Myers Squibb: Hepatitis Pipeline, 2014
  • Table 7.8 Merck & Co.: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013
  • Table 7.9 Gilead Sciences: Hepatitis C All-Oral Regimens, 2014
  • Table 7.10 Merck & Co.: Hepatitis C All-Oral Regimens, 2014
  • Table 7.11 AbbVie: Hepatitis C All-Oral Regimens, 2014
  • Table 7.12 Achillion Pharmaceuticals: Hepatitis C All-Oral Regimens, 2014
  • Table 8.1 Hepatitis C Therapies Market: Strengths and Weaknesses, 2014
  • Table 8.2 Hepatitis C Therapies Market: Opportunities and Threats, 2014-2025
  • Table 8.3 Liver Cancer: Deaths by Region, 2012
  • Table 8.4 Selected All-Oral Hepatitis C Regimens in Development, 2014
  • Table 10.1 Hepatitis C Therapies: Revenue ($bn) by Drug and Segment, 2013, 2019 & 2025
  • Table 10.2 Leading Hepatitis Treatments: Patent Expiries and Peak Revenues ($bn)

List of Figures

  • Figure 1.1 Hepatitis C Market Segmentation, 2014
  • Figure 2.1 Brief History of Hepatitis, 1947-2014
  • Figure 3.1 Hepatitis C Therapies Market by Segment (%), 2013
  • Figure 3.2 Hepatitis C Therapies Market by Segment (%), 2014
  • Figure 3.3 Hepatitis C Therapies Market: Overall Market Forecast ($bn), 2014-2025
  • Figure 3.4 Global Hepatitis C Therapies Market: Drivers and Restraints, 2014-2025
  • Figure 3.5 Leading Hepatitis C Antivirals Submarket Share (%), 2013
  • Figure 3.6 Oral Antivirals Market: Drivers and Restraints, 2014-2025
  • Figure 3.7 Oral Antivirals Submarket: Revenue Forecast ($bn), 2014-2025
  • Figure 3.8 Interferons Submarket: Market Share (%) by Drug, 2013
  • Figure 3.9 Interferons Submarket: Revenue Forecast ($bn), 2014-2025
  • Figure 3.10 Interferons Submarket: Drivers and Restraints, 2014-2025
  • Figure 3.11 Hepatitis C Submarket Shares ($bn), 2013, 2019 & 2025
  • Figure 4.1 Chronic Hepatitis C: Global Prevalence (%) by Region, 2013
  • Figure 4.2 Hepatitis C Therapies: Market Share (%) by Region, 2013
  • Figure 4.3 Hepatitis C Therapies: Market Share (%) by Region, 2019
  • Figure 4.4 Hepatitis C Therapies: Market Share (%) by Region, 2025
  • Figure 4.5 US Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.6 EU5 Hepatitis C Therapies: Market Share (%) by Country, 2013
  • Figure 4.7 EU5 Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.8 Italian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.9 Spanish Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.10 German Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.11 UK Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.12 French Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.13 Chinese Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.14 Japanese Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.15 Indian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.16 Russian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 4.17 Brazilian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
  • Figure 5.1 Sovaldi: Revenue ($bn) by Region, Q1-Q3, 2014
  • Figure 5.2 Sovaldi: Revenue Forecast ($bn), 2014-2025
  • Figure 5.3 Olysio: Recent Revenue ($bn), Q1-Q3, 2014
  • Figure 5.4 Olysio: Revenue Forecast ($bn), 2014-2025
  • Figure 5.5 Pegasys: Revenue ($bn), 2011-2014
  • Figure 5.6 Pegasys: Revenue Forecast ($bn), 2014-2025
  • Figure 5.7 Incivek: Market Share (%) by Region, 2013
  • Figure 5.8 Incivek: Revenue Forecast ($bn), 2014-2025
  • Figure 5.9 PegIntron: Recent Revenue ($bn), 2011-2014
  • Figure 5.10 PegIntron: Revenue Forecast ($bn), 2014-2025
  • Figure 5.11 Victrelis: Recent Revenue ($bn), 2011-2014
  • Figure 5.12 Victrelis: Revenue Forecast ($bn), 2014-2025
  • Figure 5.13 Harvoni: Revenue Forecast ($bn), 2014-2025
  • Figure 5.14 Daklinza: Revenue Forecast ($bn), 2014-2025
  • Figure 5.15 Sunvepra: Revenue Forecast ($bn), 2014-2025
  • Figure 7.1 Hepatitis C Therapies: Market Share (%) by Company, 2013
  • Figure 7.2 Hepatitis C Therapies: Market Share (%) by Company, 2014
  • Figure 7.3 Gilead Sciences: Revenue Share (%) by Therapeutic Area, 2013
  • Figure 7.4 Johnson & Johnson: Key Events in the Hepatitis C Drug Market, 2011-2014
  • Figure 7.5 Pegasys: Revenue ($bn), 2013, 2019 & 2025
  • Figure 7.6 Merck & Co.: Revenue Share (%) by Therapeutic Area, 2013
  • Figure 8.1 Liver Cancer: Deaths by Region, 2012
  • Figure 10.1 Hepatitis C Therapies: Revenue ($bn) by Segment, 2013, 2019 & 2025

Companies Listed

  • 3SBio
  • Abbott Laboratories
  • AbbVie
  • Achillion Pharmaceuticals
  • Alios BioPharma
  • Amega Biotech
  • American University in Cairo
  • Anadys Pharmaceuticals (now part of Roche)
  • Anhui Biochem Bio-Pharmaceutical
  • BioCryst Pharmaceuticals
  • Biolex
  • BioLineRx
  • Biosidus
  • Biota Holdings
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • CCL Pharmaceuticals
  • Centers for Disease Control and Prevention (CDC) [US]
  • Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
  • ChronTech Pharma
  • Chugai Pharmaceutical (part of Roche)
  • Cipla
  • Codexis
  • Committee for Medicinal Products for Human Use (EU)
  • Compass Biotechnologies (formerly Cyplasin)
  • Conference on Retroviruses and Opportunistic Infections
  • Corvas International (now part of Dendreon)
  • CPP Investment Board
  • Cyplasin
  • Debiopharm
  • Dendreon
  • Dong-A
  • Eli Lilly
  • Enanta Pharmaceuticals
  • European Association for the Study of the Liver (EASL)
  • European Centre for Disease Control and Prevention (ECDC)
  • European Commission (EC)
  • European Liver Patients Association (ELPA)
  • European Medicines Agency (EMA)
  • Feron
  • Food and Drug Administration (FDA) [US]
  • Genoscience
  • Getz Pharma
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • GlobeImmune
  • Health Protection Agency (HPA) [UK]
  • Hepatitis C Association
  • Hetero Labs
  • Hualida Biotech
  • Idenix Pharmaceuticals
  • Inhibitex (now part of BMS)
  • Inovio Pharmaceuticals
  • Institut de Veille Sanitaire (InVS) [France]
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
  • Intas Biopharmaceuticals
  • InterMune
  • Janssen Pharmaceutica (a subsidiary of J&J)
  • Johnson & Johnson (J&J)
  • JSC R-Pharm (Russia)
  • Kadmon Pharmaceuticals
  • LG Life Sciences
  • Medgenics
  • Medivir
  • Merck & Co.
  • Minapharm Pharmaceuticals
  • Ministry of Health [China]
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mitsubishi Tanabe Pharma
  • Mylan Laboratories
  • Nanogen Biopharmaceutical
  • National Health Service (NHS) [UK]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • Novartis
  • OctoPlus
  • Okairos
  • Oxford University
  • PanMed
  • Pharmasset (now part of Gilead)
  • Pharmstandard
  • Presidio Pharmaceuticals
  • Probiomed
  • Quest Diagnostics
  • Ranbaxy Laboratories
  • Regulus Therapeutics
  • Reliance Life Sciences
  • RFS Pharma
  • Roche
  • Santaris
  • Schering-Plough (now part of Merck & Co)
  • SciClone Pharmaceuticals
  • Scottish Medicines Consortium (SMC)
  • SCYNEXIS
  • Sequent Scientific
  • Sicor Biotech
  • State Food and Drug Administration (SFDA) [China]
  • Strides Arcolab
  • Tibotec Pharmaceuticals (a subsidiary of Janssen Pharmaceutica)
  • Transgene
  • University of Alberta
  • Valeant Pharmaceuticals International
  • Vertex Pharmaceuticals
  • Welsh School of Pharmacy (Cardiff University)
  • World Health Organization (WHO)
  • World Hepatitis Alliance
  • Xiamen Innovax Biotech
  • Xiamen University
  • Zydus Cadila Healthcare
  • ZymoGenetics (now part of BMS)
Back to Top